Last €150.06 EUR
Change Today -1.35 / -0.89%
Volume 0.0
J7Z On Other Exchanges
As of 4:15 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (J7Z) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - €156.53
52 Week Low
05/9/14 - €87.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (J7Z)

jazz pharmaceuticals plc (J7Z) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (J7Z) Details

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.

870 Employees
Last Reported Date: 11/4/14

jazz pharmaceuticals plc (J7Z) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $771.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $419.6K
Executive Vice President and General Counsel
Total Annual Compensation: $536.0K
Total Annual Compensation: $472.7K
Compensation as of Fiscal Year 2013.

jazz pharmaceuticals plc (J7Z) Key Developments

Jazz Pharmaceuticals Public Limited Company Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 10:00 AM

Jazz Pharmaceuticals Public Limited Company Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Bruce C. Cozadd, Co-Founder, Executive Chairman and Chief Executive Officer.

Jazz Pharmaceuticals plc Receives FDA Approval For Intravenous Administration Of Erwinaze

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. Prior to this approval, the only approved route of administration for Erwinaze was through intramuscular injection. With the expanded label, the formulation of Erwinaze currently on the market may now be administered to patients by either intravenous infusion or intramuscular injection. The updated product label provides data and information to help physicians understand the different administration options and determine which route of administration is most appropriate for their patients. The FDA approval was based on a pharmacokinetic study of intravenous asparaginase Erwinia chrysanthemi following hypersensitivity to E coli-derived asparaginase. The intravenous administration trial was conducted at 10 centers in the U.S. and recruited a total of 30 patients, of which 24 patients were evaluable for the primary endpoint, which was the proportion of patients having an asparaginase activity level of greater than 0.1 IU/mL 48 hours after dosing.

Jazz Pharmaceuticals Initiates Rolling NDA Submission for Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease

Jazz Pharmaceuticals plc announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for defibrotide for the treatment of severe hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. Defibrotide has been granted Fast Track Designation to treat severe VOD by the FDA.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
J7Z:GR €150.06 EUR -1.35

J7Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.22 USD +0.205
Alkermes PLC $72.19 USD +0.79
BioMarin Pharmaceutical Inc $99.65 USD +2.40
Impax Laboratories Inc $37.69 USD -0.44
Salix Pharmaceuticals Ltd $135.14 USD +7.25
View Industry Companies

Industry Analysis


Industry Average

Valuation J7Z Industry Range
Price/Earnings 100.0x
Price/Sales 9.5x
Price/Book 7.7x
Price/Cash Flow 70.2x
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at